Goldman Small Cap Research has released a new research update on OKYO Pharma Ltd., an emerging player in the ophthalmic drugs segment. The report highlights recent achievements, including the early completion of a Phase 2 trial and an increased price target due to these developments. The research update is available at goldmansmallcapresearch.com/opportunity-research/raising-price-target-to-8/.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.